Indacaterol/Glycopyrronium/Mometasone fixed dose combination for uncontrolled asthma.

Corrado PelaiaClaudia Crimi Nunzio CrimiLuisa RicciardiNicola ScichiloneGiuseppe ValentiOrnella BonavitaStefano AndaloroPaolo MoriniAndrea RizziGirolamo Pelaia

Published in: Expert review of respiratory medicine (2021)

IND/GLY/MF was superior to both IND/MF and salmeterol/fluticasone (SAL/FLU), a well-established LABA/ICS combination improving lung function in uncontrolled asthma. Moreover, IND/GLY/MF, delivered through the Breezhaler inhaler in a single inhalation, is the first inhaled therapy prescribed alongside a digital companion, a sensor and the Propeller app, allowing for improved treatment adherence, reduced rescue inhaler usage and hospitalizations, increased patient satisfaction and asthma control.

Keyphrases

lung function
cystic fibrosis
chronic obstructive pulmonary disease
air pollution
patient satisfaction
allergic rhinitis
type diabetes
cell therapy
glycemic control
combination therapy